Exelixis Stock Forecast
NASDAQ: EXELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 10:57 AM ET
EXEL analyst consensus
Consensus (18 analysts)
buy
Avg. price target
$54.53-8.64%
- Strong buy 1
- Buy 6
- Hold 10
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 18 Wall Street analysts covering Exelixis (2026-10-07), 7 rate the stock a buy or strong buy, 10 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $54.53, with a high estimate of $70.00 and a low estimate of $41.00. The average target implies downside of 8.6% from the current price of $59.69.
The spread between the highest and lowest targets is 70.7%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for EXEL.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 6% |
| Buy | 6 | 33% |
| Hold | 10 | 56% |
| Sell | 0 | 0% |
| Strong sell | 1 | 6% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $41.00 | -31.31% |
| Average target | $54.53 | -8.64% |
| High target | $70.00 | +17.27% |